Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
DiagnoCure said last week it sold its PCA3 prostate cancer biomarker assets to Hologic‘s subsidiary Gen-Probe for $4.7 million.
The purchase is slated to include $4 million in cash and the repurchase of 4.9 million series A convertible preferred shares of DiagnoCure held by Gen-Probe, valued at $744,229. Read more
Steris shares are up nearly 8% since the company last week issued its 1st post-merger guidance since its $2 billion merger with the U.K.’s Synergy Health, as investors reacted to a top-line growth forecast of 21% to 22% for fiscal 2016.
Mentor, Ohio-based Steris closed the Synergy merger Nov. 2 in a so-called inversion deal, in which it re-incorporated as a British entity.
Steris also said it expects to post adjusted earnings per share of $3.48 to $3.55 for the year ending March 31, 2016. Read more
Pulse Biosciences, which is developing pulsed electric field technology to treat solid tumors, last week filed for an initial public offering worth $20 million.
Burlingame, Calif.-based Pulse said it plans to float 5 million shares at $4 apiece, for a fully diluted valuation of $51 million. The company is developing “nano-pulse electro-signaling,” in which extremely short-duration pulsed electrical fields are directed at the tumors. It’s designed to induce a type of programmed cell death called immunogenic apoptosis, which can trigger the body’s immune response to find and kill other cells of the same type. Read more